Deep dives into drug launches, brand strategy, pharma careers and industry history — written for students and freshers who want to understand how this industry actually works, not how textbooks say it does.
E-pharmacies went from a 2% niche to a multi-billion dollar industry in under a decade. Business models, consumer behaviour, regulatory paralysis, and what comes next.
DPCO, trade margins, and what your pharmacoeconomics textbook quietly skipped.
People keep saying pharma is just like FMCG. It is not. Here is the full breakdown.
India's most prescribed paracetamol, explained properly. What it does, how much to take, side effects, pregnancy safety — and the regulatory reason 650mg became the standard.
India's revised Schedule M forces every drug manufacturer to move from basic hygiene rules to global quality risk management. Here is what changed, why it matters, and what the deadlines actually mean.
Medical reps are not sample-dropping couriers. They are trained commercial operators selling something far more valuable than a molecule — and understanding how changes how you see the entire pharma field force.
Vaccines approved in under a year. The fastest before this had taken four years. Here is how it actually happened — the science, the money, the regulatory shortcuts that were not shortcuts, and why India sat at the centre of it.
Read case study →Lipitor generated over $125 billion before its patent expired in 2011. The full story of Pfizer's pre-cliff strategy, the Ranbaxy legal fight, and what the playbook teaches about pharma lifecycle management.
Read case study →Bayer went to bed a pharmaceutical company and woke up an agrochemical defendant. The $63 billion Monsanto acquisition starved the pharma pipeline, triggered $17 billion in litigation, and wiped out €35 billion in market value.
Read case study →A sedative sold as the safest drug in the world caused birth defects in over 10,000 children. Here is what happened, why India's story is more complicated than most people know, and what it permanently changed about how drugs get approved.
Read case study →India's biggest pharma success story collapsed under data fraud allegations — and permanently changed how generic drug manufacturers are scrutinised worldwide.
Read case study →Merck pulled its blockbuster painkiller in 2004 after a placebo-controlled trial proved an undeniable link to heart attacks. The $7 billion fallout permanently changed how drug safety is monitored worldwide.
Read case study →You spend four years studying pharma and still have no idea how the industry actually works — how drugs get marketed, how brands are built, how companies decide what to launch next, and what happens when things go wrong.
Textbooks cover the science. Nobody covers the business. This blog is an honest attempt to fix that.
No expert positioning, no recycled content from other blogs. Just a fresher asking real questions, doing the research, and writing down what they find — in plain language, without assuming you already know everything.
Have a topic suggestion, a question about pharma, or want to collaborate? Send a direct email — responses within 48 hours.